HSCS
HeartSciences Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.69
P/S
565.00
EV/EBITDA
442.54
DCF Value
$-1.71
FCF Yield
-117503.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1060.2%
Operating Margin
-89939.6%
Net Margin
-97881.0%
ROE
-333.4%
ROA
-112.3%
ROIC
-119.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-2.0M | $-0.63 |
| Q2 2026 | $2.4K | $-2.4M | $-0.85 |
| Q1 2026 | $1.9K | $-2.1M | $-1.58 |
| Q4 2025 | $4.3K | $-2.1M | $-1.88 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.45
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.